6 TECH OUTLOOKAug-Sept - 2018Copyright © 2018 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.AUG-SEPT - 2018Aug-Sept - 2018, Vol 02 - 10 Published by ValleyMedia Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Editor-in-ChiefStacey SmithVisualizerAsher BlakeS NityaEditorial StaffAaron Pierce Shiv ShankerAva GarciaJenna Vegas Joshua ParkerJustin SmithCRO SPECIALSalesRichard Watson richard@pharmatechoutlook.comEditorialStacey Smith Editor-in-ChiefAs the size, complexity, duration, cost, and globalization of clinical trials has grown over the last few decades, pharmaceutical, biotech, and medical device companies have increasingly begun outsourcing clinical activities to contract research organizations (CROs). From achieving scale to accessing deep domain expertise in a given therapeutic area, CROs provide the flexibility to deliver demanding clinical research objectives. Several companies have already adopted this strategy and outsourced their processes to CROs to contain the high cost of new drug development, and navigate increasingly complex trials, regulatory hurdles, and market access concerns.Companies are looking to leverage the investments that CROs have made in new capabilities that address key developmental challenges such as big data partnerships to improve site identification, patient recruitment, health economics, and outcomes research. CROs are also expected to stay up to date with evolving regulatory requirements and collaborate with organizations such as the International Consortium for Health Outcomes Measurement, which is responsible for setting standards in benchmarking and systems for data collection.Innovation plays an increasingly important role in driving efficient drug development. CROs are brainstorming new approaches coupled with existing, tested technologies and sophisticated analytics to reduce the risk and cost of clinical drug development. It will be important for CROs to streamline their processes and reduce the number of systems involved to deliver a standardized environment on a unified, centralized platform. CROs will continue to collaborate with pharmaceutical, biotechnology, and medical device companies in the deployment of cutting-edge technology. For example, incorporating wearables and sensors in clinical trials can drive additional value in their development programs.Our aim with this edition is to help companies discover leading CROs that can add value across a variety of medical research programs. This edition features thought-leadership from subject matter experts while showcasing the prowess of innovative CROs. Let us know your thoughts.Innovation and StandardizationTECH OUTLOOKTECH OUTLOOK*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffContact Us:Phone:510-230-0395,Fax:510-894-8405Email:sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.com
< Page 5 | Page 7 >